SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-32924"
 

Search: onr:"swepub:oai:DiVA.org:umu-32924" > Effects of atenolol...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Boman, KurtUmeå universitet,Medicin (author)

Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • 2009-10-13
  • SAGE Publications,2010
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-32924
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-32924URI
  • https://doi.org/10.1177/1076029609349501DOI
  • https://gup.ub.gu.se/publication/108915URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVES: To compare the effects of the beta-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). DESIGN: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. RESULTS: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. CONCLUSION: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.

Subject headings and genre

  • fibrinolysis
  • von Willebrand factor
  • hypertension
  • left ventricular hypertrophy
  • atenolol
  • losartan
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Boman, Jenny HernestålUmeå universitet,Medicin(Swepub:umu)jeyhel99 (author)
  • Andersson, Jonas,1977-Umeå universitet,Medicin(Swepub:umu)jasaon96 (author)
  • Olofsson, Mona,1952-Umeå universitet,Medicin(Swepub:umu)mool0019 (author)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xdahbj (author)
  • Umeå universitetMedicin (creator_code:org_t)

Related titles

  • In:Clinical and applied thrombosis/hemostasis: SAGE Publications16:2, s. 146-1521076-02961938-2723

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view